Do analysts prefer NCEL or FLNA?

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 266.30%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, NCEL or FLNA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is NCEL or FLNA more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Cassava Sciences N/A -53.90% -34.20%

Do analysts rate ACRV or NCEL?

Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 640.74%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ACRV or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is ACRV or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% NLS Pharmaceutics N/A N/A N/A

Do analysts recommend TCRX or NCEL?

TScan Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 521.44%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, TCRX or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than TScan Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TScan Therapeutics $9.14M 6.91 -$129.77M -$0.96 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Do analysts rate NCEL or EDSA?

Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 27.64%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, NCEL or EDSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is NCEL or EDSA more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Edesa Biotech N/A -286.52% -75.36%

Do analysts rate OKYO or NCEL?

OKYO Pharma presently has a consensus target price of $6.33, suggesting a potential upside of 275.87%. Given OKYO Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe OKYO Pharma is more favorable than NLS Pharmaceutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, OKYO or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is OKYO or NCEL more profitable?

Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A NLS Pharmaceutics N/A N/A N/A

NLS Pharmaceutics (NCEL) Competitors

$3.25 -0.07 (-2.11%)

As of 11:27 AM Eastern

Compare

NCEL vs. FLNA, ACRV, TCRX, EDSA, and OKYO

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Cassava Sciences (FLNA), Acrivon Therapeutics (ACRV), TScan Therapeutics (TCRX), Edesa Biotech (EDSA), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry.

How does NLS Pharmaceutics compare to Cassava Sciences?

NLS Pharmaceutics (NASDAQ:NCEL) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.72, suggesting that its share price is 172% less volatile than the broader market.

In the previous week, Cassava Sciences had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.93 beat Cassava Sciences' score of 0.78 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Cassava Sciences	Positive

NLS Pharmaceutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Cassava Sciences	N/A	-53.90%	-34.20%

38.0% of Cassava Sciences shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 266.30%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NLS Pharmaceutics beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Acrivon Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.93 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Positive
NLS Pharmaceutics	Positive

NLS Pharmaceutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
NLS Pharmaceutics	N/A	N/A	N/A

Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 640.74%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Acrivon Therapeutics beats NLS Pharmaceutics on 6 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, TScan Therapeutics had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for TScan Therapeutics and 1 mentions for NLS Pharmaceutics. TScan Therapeutics' average media sentiment score of 1.19 beat NLS Pharmaceutics' score of 0.93 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
NLS Pharmaceutics	Positive

NLS Pharmaceutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. NLS Pharmaceutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
NLS Pharmaceutics	N/A	N/A	N/A

TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics has lower revenue, but higher earnings than TScan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$9.14M	6.91	-$129.77M	-$0.96	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

TScan Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 521.44%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TScan Therapeutics beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Edesa Biotech?

NLS Pharmaceutics (NASDAQ:NCEL) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 27.64%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.5% of Edesa Biotech shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Edesa Biotech had 6 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 7 mentions for Edesa Biotech and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.93 beat Edesa Biotech's score of -0.30 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Edesa Biotech	Neutral

NLS Pharmaceutics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Edesa Biotech	N/A	-286.52%	-75.36%

Summary

Edesa Biotech beats NLS Pharmaceutics on 8 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

OKYO Pharma presently has a consensus target price of $6.33, suggesting a potential upside of 275.87%. Given OKYO Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe OKYO Pharma is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OKYO Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, OKYO Pharma had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.93 beat OKYO Pharma's score of 0.58 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Positive
NLS Pharmaceutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
NLS Pharmaceutics	N/A	N/A	N/A

3.0% of OKYO Pharma shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Summary

OKYO Pharma beats NLS Pharmaceutics on 7 of the 9 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.39M	$2.90B	$6.26B	$12.44B
Dividend Yield	N/A	1.79%	2.69%	5.30%
P/E Ratio	N/A	17.66	22.35	24.23
Price / Sales	N/A	488.35	555.60	126.08
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	2.04	3.84	9.82	6.73
Net Income	-$8.30M	$75.85M	$3.56B	$336.97M
7 Day Performance	-5.80%	-2.13%	-1.16%	0.79%
1 Month Performance	-15.58%	21.60%	3.85%	5.38%
1 Year Performance	-84.60%	21.15%	27.33%	34.55%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	1.4092 of 5 stars	$3.25 -2.1%	N/A	-85.0%	$17.39M	N/A	N/A	6	Gap Up
FLNA Cassava Sciences	1.9044 of 5 stars	$1.50 +6.4%	$5.00 +233.3%	-32.4%	$72.47M	N/A	N/A	20	Gap Up
ACRV Acrivon Therapeutics	2.2697 of 5 stars	$1.67 flat	$11.67 +598.6%	+41.4%	$71.69M	N/A	N/A	58	Analyst Upgrade
TCRX TScan Therapeutics	3.5014 of 5 stars	$1.09 +1.4%	$6.00 +453.0%	-32.9%	$70.91M	$10.32M	N/A	100	News Coverage Positive News Gap Up
EDSA Edesa Biotech	1.9858 of 5 stars	$7.93 -18.2%	$5.00 -37.0%	+243.2%	$70.51M	N/A	N/A	20	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FLNA, ACRV, TCRX, EDSA, and OKYO

How does NLS Pharmaceutics compare to Cassava Sciences?

Summary

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Summary

How does NLS Pharmaceutics compare to TScan Therapeutics?

Summary

How does NLS Pharmaceutics compare to Edesa Biotech?

Summary

How does NLS Pharmaceutics compare to OKYO Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FLNA, ACRV, TCRX, EDSA, and OKYO

How does NLS Pharmaceutics compare to Cassava Sciences?

Which has more volatility and risk, NCEL or FLNA?

Does the media prefer NCEL or FLNA?

Is NCEL or FLNA more profitable?

Do insiders and institutionals have more ownership in NCEL or FLNA?

Which has better valuation & earnings, NCEL or FLNA?

Do analysts prefer NCEL or FLNA?

Summary

How does NLS Pharmaceutics compare to Acrivon Therapeutics?

Which has more volatility & risk, ACRV or NCEL?

Which has better earnings & valuation, ACRV or NCEL?

Do institutionals and insiders hold more shares of ACRV or NCEL?

Does the media refer more to ACRV or NCEL?

Is ACRV or NCEL more profitable?

Do analysts rate ACRV or NCEL?

Summary

How does NLS Pharmaceutics compare to TScan Therapeutics?

Does the media prefer TCRX or NCEL?

Is TCRX or NCEL more profitable?

Which has more risk & volatility, TCRX or NCEL?

Do institutionals and insiders have more ownership in TCRX or NCEL?

Which has higher valuation & earnings, TCRX or NCEL?

Do analysts recommend TCRX or NCEL?

Summary

How does NLS Pharmaceutics compare to Edesa Biotech?

Do analysts rate NCEL or EDSA?

Do institutionals & insiders hold more shares of NCEL or EDSA?

Which has better valuation & earnings, NCEL or EDSA?

Which has more volatility and risk, NCEL or EDSA?

Does the media prefer NCEL or EDSA?

Is NCEL or EDSA more profitable?

Summary

How does NLS Pharmaceutics compare to OKYO Pharma?

Do analysts rate OKYO or NCEL?

Which has more risk & volatility, OKYO or NCEL?

Does the media refer more to OKYO or NCEL?

Is OKYO or NCEL more profitable?

Do institutionals and insiders hold more shares of OKYO or NCEL?

Which has stronger valuation & earnings, OKYO or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools